GBIO Stock Generation Bio (GBIO, $0.37) Stochastic Oscillator left the oversold zone on May 27, 2025

GET DAILY SIGNALS

Get AI intraday signals

GBIO - Generation Bio Co

Stochastic signal

View

Odds of UP Trend

Price: $0.3707

Daily change: +$0.0006 (+0.16%)

Daily volume: 376.7K

Capitalization: $24.9M

Industry: Biotechnology

Momentum Indicator for GBIO turns negative, indicating new downward trend

GBIO saw its Momentum Indicator move below the 0 level on June 12, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In of the 86 cases, the stock moved further down in the following days. The odds of a decline are at .

Technical Analysis (Indicators)

Bearish Trend Analysis

GBIO moved below its 50-day moving average on June 12, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GBIO broke above its upper Bollinger Band on June 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for GBIO just turned positive on May 13, 2025. Looking at past instances where GBIO's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for GBIO crossed bullishly above the 50-day moving average on June 10, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GBIO advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 158 cases where GBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.337) is normal, around the industry mean (16.954). P/E Ratio (0.000) is within average values for comparable stocks, (59.376). GBIO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.335). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (1.004) is also within normal values, averaging (257.043).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. GBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.